Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Sep
10
2015
Clinical Trials As Prior Art: PTAB Denies Bass IPR Petition With Only A "Hope" of Efficacy Foley & Lardner LLP
Sep
10
2015
FDA Releases Initial FSMA Final Rules Armstrong Teasdale
Sep
10
2015
FDA Releases Long-Awaited Biological Naming Draft Guidance and Proposed Rule McDermott Will & Emery
Sep
8
2015
What’s in a Name? When You’re Selling a Food with an Established Federal Standard of Identity, a Whole Lot! Mintz
Sep
8
2015
Patent Trial and Appeal Board Boots Bass Tecfidera IPR On The Merits Foley & Lardner LLP
Sep
4
2015
Wine Seller Victory in Illinois Qui Tam Lawsuit Horwood Marcus & Berk Chartered
Sep
4
2015
Sandoz Launches First Biosimilar Drug in U.S.
Sep
4
2015
Marijuana-Legalization Efforts and Their Impact on the Presidential Race Jackson Lewis P.C.
Sep
3
2015
NLRB Says Beer Dealer’s Refusal-To-Drug-Test Firing Doesn’t Mix With “Weingarten Rights” Jackson Lewis P.C.
Sep
3
2015
Another Claim Bites the Dust left by Teva v. Sandoz
Sep
3
2015
Long-Awaited Notice of Proposed Rulemaking for Federal Policy for the Protection of Human Subjects Released Faegre Drinker
Sep
3
2015
Update in Amgen v. Sandoz re: Biosimilar Applications Michael Best & Friedrich LLP
Sep
2
2015
Minnesota Federal Court Finds “Field Preemption” of Minnesota Drug Testing Statute Jackson Lewis P.C.
Sep
1
2015
Makers’ Mark Two: Bourbon Distiller Slips another “Handmade” False Advertising Suit Proskauer Rose LLP
Sep
1
2015
Wait Continues for Release of First FSMA Final Rules Armstrong Teasdale
Sep
1
2015
FDA’s New Four-Letter Guidance on Biosimilars Mintz
Aug
31
2015
Getting Serious about Palcohol: Powdered Alcohol Faegre Drinker
Aug
31
2015
An Update on Biosimilar Activity in the U.S. Michael Best & Friedrich LLP
Aug
30
2015
Another FTC Conduct Case to Bolster Generic Drug Competition: Pharmaceuticals Charged with Illegal Non-Compete for Generic ADHD Drug Sales Mintz
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
Aug
28
2015
FDA’s Proposed Naming Convention for Biologics Foley & Lardner LLP
Aug
28
2015
Health Resources and Service Administration (HRSA) Issues Proposed “Omnibus Guidance” Epstein Becker & Green, P.C.
Aug
28
2015
Amgen Inc., et al. v. Sandoz, Inc.: Shall Means Shall . . . Unless It Doesn’t McDermott Will & Emery
Aug
27
2015
Food Standards of Identity Remain a Focus of FDA Regulatory Action Michael Best & Friedrich LLP
Aug
27
2015
Sixth Circuit Assesses Class Action Criteria in Digestive Drug Litigation Squire Patton Boggs (US) LLP
Aug
27
2015
Amgen And Apotex Do The Biosimilar Patent Dance Foley & Lardner LLP
Aug
26
2015
Kyle Bass Loses Round 1 Of IPR Attack Against Pharma/Biotech Patents
Aug
26
2015
Trademarking: Capri Sun Says “Respect the Pouch” IMS Legal Strategies
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins